Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Intercure Ltd (INCR-U.TO)

Intercure Ltd (INCR-U.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 169,817
  • Shares Outstanding, K 45,573
  • Annual Sales, $ 219,677 K
  • Annual Income, $ 4,690 K
  • 60-Month Beta N/A
  • Price/Sales 1.47
  • Price/Cash Flow 48.79
  • Price/Book 1.23
Trade INCR-U.TO with:
  • Price/Earnings ttm 17.94
  • Earnings Per Share ttm 0.74
  • Most Recent Earnings 0.16 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.50 +9.14%
on 01/18/23
3.94 -3.05%
on 01/09/23
+0.31 (+8.83%)
since 01/04/23
3-Month
3.35 +14.03%
on 12/29/22
5.42 -29.52%
on 11/15/22
-1.13 (-22.83%)
since 11/01/22
52-Week
3.35 +14.03%
on 12/29/22
8.00 -52.25%
on 02/11/22
-2.47 (-39.27%)
since 02/07/22

Most Recent Stories

More News
Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), ( “Organigram”) a leading Canadian licensed producer of cannabis and Canndoc Ltd. (“Canndoc”), a subsidiary of InterCure Ltd. (NASDAQ: INCR) (TSX:INCR.U)...

INCR.TO : N/A (unch)
OGI : 0.8770 (-0.79%)
OGI.TO : 1.16 (-1.69%)
INCR-U.TO : 3.82 (+1.33%)
INCR : 3.78 (+0.80%)
Stocks in play: Intercure Ltd

Today announced record preliminary financial results for the Third quarter of 2022. Preliminary Third ...

INCR-U.TO : 3.82 (+1.33%)
InterCure to Release its Q2 2022 Results and Hold a Conference Call

Conference call scheduled for Tuesday, August 16, 2022, at 8:30am ET...

INCR.TO : N/A (unch)
INCR-U.TO : 3.82 (+1.33%)
INCR : 3.78 (+0.80%)
Stocks in play: InterCure Ltd.

Announced record preliminary financial results for the second quarter of 2022. Record revenue estimated ...

INCR-U.TO : 3.82 (+1.33%)
InterCure Reports Record Preliminary 2022 Second Quarter Revenue – More Than Double YoY and 9% QoQ Growth

Estimated revenue reaches CAD$36 million 1(a record NIS 95 million) Anticipates continued increases in EBITDA Revenue growth expected to...

INCR.TO : N/A (unch)
INCR : 3.78 (+0.80%)
INCR-U.TO : 3.82 (+1.33%)
Stocks in play: Intercure Ltd

Announced today the successful opening of the first flagship Cookies store in Austria, located in the ...

INCR-U.TO : 3.82 (+1.33%)
InterCure and Cookies Launch Flagship Retail Location in Vienna, Austria

NEW YORK and TORONTO and HERZLIYA, Israel, June 21, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) ("InterCure" or the...

INCR.TO : N/A (unch)
INCR-U.TO : 3.82 (+1.33%)
INCR : 3.78 (+0.80%)
InterCure and Cookies Successfully Launch Flagship Pharmacy in Be'er Sheva, Israel

Cookies Be'er Sheva is the largest medical cannabis dedicated pharmacy in Israel...

INCR.TO : N/A (unch)
INCR-U.TO : 3.82 (+1.33%)
INCR : 3.78 (+0.80%)
InterCure Begins 2022 with Record Breaking First Quarter Financial Results

Record revenue of $341 million in the first quarter of 2022 Adjusted EBITDA2 increased almost 110% year-over-year to $8 million Net income of $6...

INCR.TO : N/A (unch)
INCR : 3.78 (+0.80%)
INCR-U.TO : 3.82 (+1.33%)
InterCure to Release its Q1 2022 Results and Hold a Conference Call

Conference call scheduled for Tuesday, May 17, 2022, at 8:00am ET...

INCR.TO : N/A (unch)
INCR-U.TO : 3.82 (+1.33%)
INCR : 3.78 (+0.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 3.82
2nd Resistance Point 3.82
1st Resistance Point 3.82
Last Price 3.82
1st Support Level 3.82
2nd Support Level 3.82
3rd Support Level 3.82

See More

52-Week High 8.00
Fibonacci 61.8% 6.22
Fibonacci 50% 5.68
Fibonacci 38.2% 5.13
Last Price 3.82
52-Week Low 3.35

See More

Business Summary

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations.

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar